Work at Shanghai Jeyou Pharmaceutical Co. Ltd. has led to the identification of new thioether-substituted galactopyranoside derivatives acting as galectin-3 (LGALS3) inhibitors. As such, they are reported to be useful for the treatment autoimmune disease, cancer, cardiovascular disorders, diabetic nephropathy and more.